Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine.
收藏DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008277/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of the
SB257049 candidate malaria vaccine when co-administered with Vitamin A, measles, rubella and
yellow fever vaccines to children aged 6 months at the first vaccination.
提供机构：
Vivli
创建时间：
2022-07-18
